OncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Sat, 16 May 2026 21:14:20 +00005en-us14447https://www.onclive.com/newshttps://www.onclive.com/logo.webphttps://www.onclive.com/view/preoperative-intravesical-mitomycin-c-before-turbt-cuts-recurrence-risk-77-percent-nmibc-5-yearshttps://www.onclive.com/view/preoperative-intravesical-mitomycin-c-before-turbt-cuts-recurrence-risk-77-percent-nmibc-5-years<![CDATA[Two doses of intravesical mitomycin-C administered before TURBT produced a 77% reduction in the risk of recurrence or death vs TURBT alone in NMIBC.]]>Sat, 16 May 2026 17:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/genomic-disease-burden-markers-pd-l1-expression-predictive-of-por-with-neoadjuvant-gem-idrs-cetrelimab-in-mibchttps://www.onclive.com/view/genomic-disease-burden-markers-pd-l1-expression-predictive-of-por-with-neoadjuvant-gem-idrs-cetrelimab-in-mibc<![CDATA[A biomarker analysis of SunRISe-4 found that high baseline TMB, GBD, and PD-L1 expression were associated with pathologic overall response to the regimen. ]]>Sat, 16 May 2026 16:00:20 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-croll-on-radiographic-size-change-vs-irrvt-after-neoadjuvant-therapy-in-rcchttps://www.onclive.com/view/dr-croll-on-radiographic-size-change-vs-irrvt-after-neoadjuvant-therapy-in-rcc<![CDATA[Benjamin Croll, MD, discusses findings from a study of the correlation between radiographic response and pathologic response in RCC.]]>Fri, 15 May 2026 22:42:36 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-t-dxd-for-early-stage-her2-breast-cancerhttps://www.onclive.com/view/fda-approves-t-dxd-for-early-stage-her2-breast-cancer<![CDATA[The FDA approved trastuzumab deruxtecan for the adjuvant and neoadjuvant treatment of select early-stage HER2-positive breast cancer.]]>Fri, 15 May 2026 22:22:07 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-garzotto-on-aglatimagene-besadenovec-plus-valacyclovir-and-ebrt-in-localized-prostate-cancerhttps://www.onclive.com/view/dr-garzotto-on-aglatimagene-besadenovec-plus-valacyclovir-and-ebrt-in-localized-prostate-cancer<![CDATA[Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.]]>Fri, 15 May 2026 21:46:32 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-cirstea-on-sequencing-considerations-in-r-r-multiple-myelomahttps://www.onclive.com/view/dr-cirstea-on-sequencing-considerations-in-r-r-multiple-myeloma<![CDATA[Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.]]>Fri, 15 May 2026 21:04:27 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-hafron-on-the-fda-approval-of-adjuvant-atezolizumab-in-mrd-mibchttps://www.onclive.com/view/dr-hafron-on-the-fda-approval-of-adjuvant-atezolizumab-in-mrd-mibc<![CDATA[Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.]]>Fri, 15 May 2026 20:34:44 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/durvalumab-plus-bcg-reduces-high-risk-nmibc-recurrence-or-death-risk-by-32-percent-in-phase-3-potomac-trialhttps://www.onclive.com/view/durvalumab-plus-bcg-reduces-high-risk-nmibc-recurrence-or-death-risk-by-32-percent-in-phase-3-potomac-trial<![CDATA[Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.]]>Fri, 15 May 2026 20:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/darolutamide-plus-adt-yields-significant-os-benefit-in-mhspchttps://www.onclive.com/view/darolutamide-plus-adt-yields-significant-os-benefit-in-mhspc<![CDATA[Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.]]>Fri, 15 May 2026 19:49:57 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/onclive-weekly-news-quiz-5-15-2026-did-you-catch-3-new-fda-oncology-approvals-https://www.onclive.com/view/onclive-weekly-news-quiz-5-15-2026-did-you-catch-3-new-fda-oncology-approvals-<![CDATA[Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.]]>Fri, 15 May 2026 19:30:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/pembrolizumab-plus-bcg-elicits-92-cr-rate-in-bcg-naive-very-high-risk-t1-nmibchttps://www.onclive.com/view/pembrolizumab-plus-bcg-elicits-92-cr-rate-in-bcg-naive-very-high-risk-t1-nmibc<![CDATA[Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.]]>Fri, 15 May 2026 19:01:11 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-adjuvant-atezolizumab-for-mrd-muscle-invasive-bladder-cancerhttps://www.onclive.com/view/fda-approves-adjuvant-atezolizumab-for-mrd-muscle-invasive-bladder-cancer<![CDATA[The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.]]>Fri, 15 May 2026 16:59:49 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/detalimogene-voraplasmid-yields-54-cr-rate-in-heavily-pretreated-bcg-unresponsive-nmibc-with-cishttps://www.onclive.com/view/detalimogene-voraplasmid-yields-54-cr-rate-in-heavily-pretreated-bcg-unresponsive-nmibc-with-cis<![CDATA[TRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff. ]]>Fri, 15 May 2026 16:47:38 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/roswell-park-team-members-take-part-in-global-conference-dedicated-to-indigenous-peoples-and-cancerhttps://www.onclive.com/view/roswell-park-team-members-take-part-in-global-conference-dedicated-to-indigenous-peoples-and-cancer<![CDATA[Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.]]>Fri, 15 May 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/poll-findings-highlight-the-most-anticipated-gu-cancer-abstracts-at-asco-2026https://www.onclive.com/view/poll-findings-highlight-the-most-anticipated-gu-cancer-abstracts-at-asco-2026<![CDATA[GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.]]>Fri, 15 May 2026 14:22:44 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/onclive-polls-reveal-picks-for-top-gi-cancer-abstracts-areas-of-interest-at-asco-2026https://www.onclive.com/view/onclive-polls-reveal-picks-for-top-gi-cancer-abstracts-areas-of-interest-at-asco-2026<![CDATA[Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.]]>Fri, 15 May 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/prevention-and-personalization-drive-the-future-of-oncodermatology-in-melanomahttps://www.onclive.com/view/prevention-and-personalization-drive-the-future-of-oncodermatology-in-melanoma<![CDATA[Beth McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.]]>Fri, 15 May 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/avb-001-encapsulated-il-2-cell-therapy-shows-safety-and-immune-activity-in-platinum-resistant-hgsochttps://www.onclive.com/view/avb-001-encapsulated-il-2-cell-therapy-shows-safety-and-immune-activity-in-platinum-resistant-hgsoc<![CDATA[AVB-001 was tolerable and activated CD8+ and CD4+ T cells without regulatory T-cell expansion in platinum-resistant high-grade serous ovarian carcinoma.]]>Thu, 14 May 2026 22:30:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-hunter-on-luspatercept-and-other-treatment-options-for-anemia-in-myelofibrosishttps://www.onclive.com/view/dr-hunter-on-luspatercept-and-other-treatment-options-for-anemia-in-myelofibrosis<![CDATA[Anthony M. Hunter, MD, discusses treatment decision-making for the management of anemia in myelofibrosis.]]>Thu, 14 May 2026 21:18:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-jones-on-the-protective-benefit-and-tolerability-of-glp-1-agonists-vs-aspirin-for-crc-preventionhttps://www.onclive.com/view/dr-jones-on-the-protective-benefit-and-tolerability-of-glp-1-agonists-vs-aspirin-for-crc-prevention<![CDATA[Colton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.]]>Thu, 14 May 2026 20:27:40 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/io-in-nmibc-radioligand-therapy-in-mhspc-highlight-key-presentations-to-watch-at-aua-2026https://www.onclive.com/view/io-in-nmibc-radioligand-therapy-in-mhspc-highlight-key-presentations-to-watch-at-aua-2026<![CDATA[Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.]]>Thu, 14 May 2026 20:13:56 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/single-agent-ibrutinib-yields-durable-responses-over-10-years-in-cll-with-and-without-tp53-aberrationshttps://www.onclive.com/view/single-agent-ibrutinib-yields-durable-responses-over-10-years-in-cll-with-and-without-tp53-aberrations<![CDATA[Ibrutinib monotherapy produced durable efficacy over 10 years in patients with or without TP53-mutated chronic lymphocytic leukemia.]]>Thu, 14 May 2026 19:24:02 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/imaging-clues-that-raise-suspicion-for-diffuse-midline-gliomahttps://www.onclive.com/view/imaging-clues-that-raise-suspicion-for-diffuse-midline-glioma<![CDATA[n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG. ]]>Thu, 14 May 2026 17:35:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/two-diseases-that-share-a-name-defining-glioblastoma-and-diffuse-midline-glioma-under-the-2021-who-classificationhttps://www.onclive.com/view/two-diseases-that-share-a-name-defining-glioblastoma-and-diffuse-midline-glioma-under-the-2021-who-classification<![CDATA[In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.]]>Thu, 14 May 2026 17:30:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/evolving-strategies-for-myelofibrosis-associated-anemia-highlight-persistent-gaps-in-biomarker-guidancehttps://www.onclive.com/view/evolving-strategies-for-myelofibrosis-associated-anemia-highlight-persistent-gaps-in-biomarker-guidance<![CDATA[Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.]]>Thu, 14 May 2026 17:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/perioperative-durvalumab-plus-neoadjuvant-ev-displays-efs-os-benefits-vs-soc-in-mibchttps://www.onclive.com/view/perioperative-durvalumab-plus-neoadjuvant-ev-displays-efs-os-benefits-vs-soc-in-mibc<![CDATA[Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.]]>Thu, 14 May 2026 16:32:27 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/rintatolimod-plus-pembrolizumab-and-cisplatin-displays-50-orr-in-recurrent-ovarian-cancerhttps://www.onclive.com/view/rintatolimod-plus-pembrolizumab-and-cisplatin-displays-50-orr-in-recurrent-ovarian-cancer<![CDATA[The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer. ]]>Thu, 14 May 2026 16:16:47 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dana-farber-study-finds-stage-iv-breast-cancer-increasing-in-incidence-and-proportion-over-the-last-decadehttps://www.onclive.com/view/dana-farber-study-finds-stage-iv-breast-cancer-increasing-in-incidence-and-proportion-over-the-last-decade<![CDATA[A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses. ]]>Thu, 14 May 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/revelution-2-trial-is-evaluating-cardiovascular-risk-with-relugolix-plus-abiraterone-acetate-in-high-risk-prostate-cancerhttps://www.onclive.com/view/revelution-2-trial-is-evaluating-cardiovascular-risk-with-relugolix-plus-abiraterone-acetate-in-high-risk-prostate-cancer<![CDATA[Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.]]>Thu, 14 May 2026 14:34:16 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/clinical-implementation-and-surveillance-strategieshttps://www.onclive.com/view/clinical-implementation-and-surveillance-strategies<![CDATA[]]>Thu, 14 May 2026 13:10:09 GMTOncLiveusOncLive Articles